comparemela.com

Latest Breaking News On - Rare syndromes - Page 1 : comparemela.com

UCB : presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting -April 12, 2024 at 01:05 am EDT

UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology Annual Meeting Diverse and.

Bruxelles capitaleUnited statesLaurent schotsDaphne teoNick francisDonatello crocettaBecky maloneJim baxterAntje witteMike davisCorporate communicationsGlobal communicationsGroup of companiesAmerican academy of neurologyUcb incAdvisory committee on immunization practices

UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

Study presents new persistence analysis of FINTEPLA, evaluating the efficacy and tolerability of FINTEPLA over a span of 12 months1 Real-world data looks into the need for resources to support caregivers – both parents and siblings – of people living with developmental and epileptic encephalopathies such as Dravet and Lennox-Gastaut syndromes in the transition from […]

United statesBruxelles capitaleBecky maloneLauried baileyTom stantonBrad chapmanAntje witteRare epilepsy parentsA survey of rare epilepsy parentsProgram see boxed warningGuideline developmentGroup of companiesEpilepsy foundationCorporate communicationsChild neurology foundationBull world health organ

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

UCB will present 29 abstracts, including 4 late breakers, at American Epilepsy Society Annual Meeting 2023 highlighting clinical, health economic and.

United statesWith ofRegion flamandeBruxelles capitaleMike davisJacobs le vanLacosamide monotherapyAntje witteBrad chapmanBecky maloneAlexza pharmaceuticals incCorporate communicationsSubgroup data from the internationalAmerican epilepsy society annual meetingProgram see boxed warningCommunity pharmacist

NAYZILAM® (midazolam) Results Published in Epilepsy & Behavior Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

Median time to return to full baseline function occurred within 90 minutes following outpatient treatment with NAYZILAM® (midazolam) nasal spray, with a.

Bruxelles capitaleBecky maloneBrad chapmanAntje witteUs communicationsDrug administrationEpilepsy foundationBull world health organGroup of companiesUcb incRare syndromesSafety informationConcomitant usePrescribing informationEuronext brusselsWorld health

UCB presents new data at 35th International Epilepsy Congress (IEC) highlighting important advancements across Fintepla®▼(fenfluramine) oral solution and broader epilepsies portfolio

UCB presents new data at 35th International Epilepsy Congress (IEC) highlighting important advancements across Fintepla®▼(fenfluramine) oral solution and broader epilepsies portfolio

United kingdomBruxelles capitaleCity ofOrrin devinskyEncephalopathies deesHelen crossMike davisInstitute of child healthEuropean society of cardiologyLangone health comprehensive epilepsy centerInternational epilepsy congressEuropean respiratory societySeizure termination projectRapid early seizure terminationGlobal epilepsyRare syndromes

vimarsana © 2020. All Rights Reserved.